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THE POTENTIAL BENEFIT OF ESOPHAGEAL SPARING DURING 
PALLIATIVE RADIOTHERAPY FOR LUNG CANCER  
Patrick V Granton, David A Palma, Alexander V Louie 
University of Western Ontario, London, ON 
 
Purpose:  A 2007 meta-analysis of several randomized controlled 
trials assessing optimal doses for palliative lung radiation 
concluded that radiation doses of 35 Gy10 or greater improved 
overall survival at one and two years compared to lower doses at 
the cost of an increased toxicity related to esophagitis. 
Esophageal sparing has been proposed as a mechanism of 
reducing this toxicity. A planning study was initiated to assess 
the potential impact of esophageal-sparing IMRT (ES-IMRT) for 
palliative lung radiotherapy, compared to the current standard 
of care using parallel-opposed pair beams (POP). 
Methods and Materials:  In this institutional research ethics 
board-approved study, patients with lung cancer treated to a 
dose of 30 Gy in 10 fractions between August 2015 and January 
2016 were identified. Additional inclusion criteria required the 
D50 to contain at least 5 cm of esophagus. The radiation 
treatment plans were optimized using ES-IMRT by limiting the 
max esophageal point dose to 80% of the prescription. This was 
achieved by creating a 5 mm ring around the esophagus. If any 
portion of the GTV was within this ring, the coverage was 
compromised such that a point dose could receive as low as 80% 
of the intended prescription. Both the clinical POP and optimized 
ES-IMRT plans were evaluated for the likelihood of esophagitis (≥ 
Grade 2) and pneumonitis (≥ Grade 2), using published Lyman-
Kutcher-Burman normal tissue complication probabilities (LKB-
NTCP) models. The input parameters for the LKB models were 
D50 = 44.9, n = 0.34, m = 0.34 and D50 = 29.9, n = 1, m = 0.41 
for esophagitis and pneumonitis, respectively. The mean 
normalized total dose (NTD mean) of the PTV, and the mean dose 
to the esophagus (esophageal mean) and lung (lung mean) were 
determined.  
Results:  A total of 13 patients met our inclusion criteria and 
were analyzed, of which 11/13 had the GTV directly abutting the 
esophagus. The median [range] of the GTV and PTV were 90.6 cc 
[22.3 – 199.8] and 321.8 cc [164.1 – 564.9], respectively. Using 
ES-IMRT, the median esophageal mean and lung mean dose 
reduced from 17.0 and 7.9 Gy to 6.8 and 7.7 Gy, respectively. 
Using the LKB model, the theoretical probability of symptomatic 
esophagitis and pneumonitis reduced from 13 to 1%, and from 5 
to 3%, respectively. The median clinical POP NTDmean was 32.8 
Gy, while the median ES-IMRT NTDmean was 33.2 Gy.  
Conclusions:  Advanced radiotherapy techniques such as ES-IMRT 
may have clinical utility in reducing treatment-related toxicity 
in advanced lung cancer patients. Our data suggests that the rate 
of esophagitis can be reduced from 13 to 1%, without 
compromising tumour control. The results of this planning study 
will inform the design of a Phase II randomized controlled trial, 
Palliative Radiation of Advanced Central lung Tumours with 
Intentional Avoidance of the Esophagus (PROACTIVE). 
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QUANTIFYING THE OUTCOME OF RADIATION THERAPY PEER 
REVIEW AND IDENTIFYING THE OPTIMAL TIMING FOR QUALITY 
ASSURANCE MEETINGS WITHIN THE RADIOTHERAPY PLANNING 
PROCESS  
Joanna Mackenzie1, Gillian Graham2, Robyn Banerjee3, Elizabeth 
Kurien3, Tien Phan3, Ivo Olivotto2 
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Purpose: To document and evaluate outcomes of weekly, 
disease-site specific, radiation therapy (RT) peer review quality 
assurance (QA) rounds at a Canadian cancer centre.  
Methods and Materials: In compliance with Canadian 
Partnership for Quality Radiotherapy QA guidelines, seven 
disease-site specific, RT QA rounds were conducted by Radiation 
Oncologists (ROs) at a mid-sized cancer centre but outcomes 
were not formally categorized or documented. From January 6 
to May 5, 2015, outcomes of each case reviewed at (i) Breast, (ii) 
Head and Neck (including thyroid and cutaneous cases) and (iii) 
Lung tumour QA rounds were recorded prospectively. Each RT 
plan was assigned an outcome: A (no change required), B (issue 
to consider for future patients), or C (change required before 
next fraction). Following an initial audit, a standard 
nomenclature was developed and adopted by all seven disease-
site QA meetings from June 2015. 
Results: Two hundred and eleven RT plans prescribed by 20 ROs 
were peer reviewed at 43 QA meetings. Twenty-eight percent 
were reviewed after contouring (prior to plan development) and 
72% were reviewed after RO plan approval. For plans reviewed 
post-contouring, 26% had a ‘B’ and 10% had a ‘C’ outcome. For 
post-planning reviews, the ‘B’ and ‘C’ rates were 12% and 9%, 
respectively. Eighty-eight percent of ‘C’ outcomes resulted in 
plan changes prior to further RT. Only 55% of ‘C’ deviations 
would have been detected at the post-contouring stage. The 
most common reason for a B or C outcome was a 
recommendation for change in target volume definition. 
Adoption of this classification across all seven disease sites 
resulted in a global C outcome rate of 4%, among 732 cases 
reviewed between June and December 2015. 
Conclusions: Routine peer review of RT plans improved plan 
quality prior to treatment delivery. The optimal timing for QA 
meetings was deemed to be at the post-planning stage. 
Widespread successful rollout demonstrated the feasibility of the 
documentation approach across disease sites. 
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LARYNGEAL MOTION DYNAMICS USING 4D-COMPUTED 
TOMOGRAPHY AND DYNAMIC MAGNETIC RESONANCE IMAGING  
Houda Bahig, Félix P. Nguyen-Tan, Edith Filion, David Roberge, 
Pensavan Thanomsack, Robert Doucet, Danis Blais, Louise 
Lambert 
Centre Hospitalier de l'Université de Montréal, Montreal, QC 
 
Purpose: To assess the dynamics of laryngeal motion in early 
glottic cancer in order to determine safe margins for partial 
larynx IMRT (PL-IMRT), as well as to evaluate dosimetric 
advantage of PL-IMRT.  
Methods and Materials: This prospective study included patients 
with T1-2N0 glottic cancer treated with whole larynx IMRT (WL-
IMRT). Pre- and mid-treatment 4D-CT allowed for assessment of 
larynx excursion during swallowing and in resting position. 
Sagittal MRI fluoroscopy was also obtained to assess swallowing 
frequency. For 10 patients, PL-IMRT plans were calculated using 
margins derived from 4D-CT analysis.  
Results: Twenty patients were accrued between 2015 and 2016. 
Over two minutes, median swallowing frequency was 1 (0-5) and 
was significantly reduced to 0 with instruction not to swallow. 
Median mid-treatment swallowing frequency was 0, even without 
specific instructions. Median amplitude of larynx excursion 
during swallowing was 23 mm (15-30), 1 mm (0-3), 6 mm (2-9) 
and 1 mm (0-3) in the superior, inferior, anterior and posterior 
directions, respectively, and remained similar mid-treatment. 
When not swallowing, median larynx excursion reached 4 mm (1-
6) and 2 mm (1-2) in superior-inferior and antero-posterior 
directions, respectively. 4D-CT analysis unexpectedly revealed 
that the planning CT had not been acquired in resting position in 
one patient. In up to 30% of patients, anatomic changes resulted 
in a 4 mm larynx shift in the SI direction and 2 mm in the AP 
direction in mid-treatment compared to pre-treatment imaging. 
PL-IMRT would have allowed for a relative reduction of mean 
doses to the ipsilateral carotid, contralateral carotid, 
contralateral arythenoid and larynx of 72%, 84%, 61% and 26%, 
respectively. Using an 8 mm ITV for PL-IMRT, swallowing would 
only result in CTV excursion beyond the 95% IDL for a median of 
0.8 seconds (0.2-1.8). 
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Conclusions: Dosimetric impact of swallowing is insignificant as 
this motion is rare, rapid and easily suppressed by patients. 
There is however a risk of systematic miss-targeting if the 
planning CT is not acquired with the larynx in resting position. 
Anatomic changes during treatment are associated with a 
laryngeal shift in a significant proportion of patients, which can 
justify the use of daily soft-tissue imaging in laryngeal IGRT. An 
8 mm ITV margin accounting for non-swallowing laryngeal motion 
in PL-IMRT would allow for a safe and significant dose reduction 
to organs at risk. 
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PATTERNS OF CARE AMONG CANADIAN RADIATION ONCOLOGISTS 
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FOR PATIENTS WITH PROSTATE CANCER  
Bonnie Bristow1, Mohammed Aldehaim2, Katija Bonin2, Chee Ka 
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2Sunnybrook Health Sciences Centre, Toronto, ON 
3University of Toronto, Toronto, ON 
 
Purpose: The American Society for Radiation Oncology (ASTRO) 
and American Urological Association (AUA) developed post-
prostatectomy radiotherapy (RT) guidelines to aid patient 
counselling regarding adjuvant (ART) and salvage radiotherapy 
(SRT). The objective of this study was to examine awareness and 
compliance of these guidelines among Canadian radiation 
oncologists (RO) and urologists (U). 
Methods and Materials: An online 28-item survey was developed, 
pretested and distributed by Canadian Association of Radiation 
Oncology (CARO) and Canadian Urology Association (CUA) to RO 
and U that treat prostate cancer. Similarities and differences 
between RO and U were examined using Wilcoxon rank sum test 
and Chi-square test. Only p-values for significant findings 
reported. 
Results: Fifty-two out of 87 RO and 76/570 U responded to the 
survey. Ninety percent of RO and 40% U practiced in academic 
centres. Eighty-two percent of RO and 49% U had read the 
guidelines (p < 0.001). Sixty-seven percent RO and 83% U always 
informed patients about possible adverse pathological findings 
post radical prostatectomy (RP). Sixty-one percent RO and 48% U 
inform patients about uncertainty of using ART on development 
of metastatic disease and overall survival (p = 0.025). ART was 
considered for seminal vesicle invasion (77% RO, 68% U), 
extracapsular extension (72% RO, 35% U; p < 0.001), and positive 
margin (84% RO, 57% U; p = 0.004). Seventy-six percent RO and 
51% U recommended ART > 50% of the time for adverse 
pathological findings post RP (p = 0.011). Seventy-one percent 
RO and 49% U agreed that ART provided long-term biochemical 
control benefit but not overall survival benefit. Sixty-eight 
percent RO and 56% U suggest RT two to six months post-surgery. 
Percentage of respondents who always informed patients that 
detectable or rising PSA post-RP were associated with metastatic 
disease (36% RO, 46% U) or death from disease (21% RO, 19% U). 
Seventy-seven percent of RO and 93% of U always monitored 
post-RP PSA to enable early SRT (p = 0.016). Seventy-three 
percent RO and 84% U agreed that biochemical recurrence should 
be defined as detectable or rising PSA ≥ 0.2 ng/ml with second 
confirmatory level ≥ 0.2 ng/ml after RP (p = 0.199). Fifty-nine 
percent of RO and 43% U would always refer patients with 
biochemical recurrence without evidence of distant metastases 
for SRT, but 24% of RO and 3% of U would not. Ninety percent of 
RO and 70% U would inform patients that the effectiveness of RT 
for PSA recurrence is greatest when given at lower PSA values (p 
= 0.011). 
Conclusions: Considerably less U had read the guidelines 
compared to RO. There was concurrence about the level of 
awareness for some parts of the guidelines; however, other areas 





DOES PEER REVIEW OF RADIATION TREATMENT PLANS IMPACT 
CLINICAL CARE? A SYSTEMATIC REVIEW OF THE LITERATURE 
Kelsey Brunskill, Gabriel Boldt, Timothy K. Nguyen, Alexander 
V. Louie, David A. Palma 
University of Western Ontario, London, ON 
 
Purpose: Peer review of radiation plans is recommended as an 
approach to improving patient safety and quality of care. 
However, peer review rounds are resource-intensive, and their 
impact on clinical care is not well-quantified. The objective of 
this study was to undertake a systematic review of the literature 
to assess the impact of peer review on clinical care. 
Methods and Materials: A systemic review of the literature was 
conducted according to PRISMA guidelines, including MEDLINE, 
EMBASE, and abstracts from relevant radiation oncology 
meetings. For inclusion, studies were required to report the 
impact of physician peer review on at least one element of 
treatment planning (e.g. target volume/organ at risk 
delineation, dose prescription, or dosimetry). Surveys in which 
radiation oncologists were asked to estimate the impact of peer 
review on treatment planning were also included to ascertain 
physician perspective on the clinical impact of peer review. 
Studies reporting central review of contours in clinical trials 
were excluded. All proportions reported represent weighted 
averages across studies. 
Results: The initial search yielded 882 potentially eligible 
studies. Full-text review was performed independently by two 
researchers, with discrepancies settled by a third. In total, 16 
studies met inclusion criteria and were included in the final 
analysis. Twelve studies, involving 12,239 patients, reported 
patient outcomes whereas, four surveys reported oncologists’ 
estimates of clinical impact. Studies were recent, with the 
majority (75%) published since 2010. Twelve studies reported on 
multiple tumour sites, while single-site studies included head 
and neck (n = 1), lung (n = 2), and breast (n = 1). In most studies, 
peer review occurred before the start of radiotherapy or within 
the first few fractions. Overall, peer review resulted in 
modifications to 10.7% of patient plans. Five studies 
differentiated between minor versus major changes and reported 
averages of 7.5% minor changes and 2.5% major changes. From 
the survey studies, oncologists estimate that modifications 
occurred in 6% of treatment plans. 
Conclusions: Based on a systematic review of the literature, 
peer review results in changes in clinical care in approximately 
one out every nine cases overall, with major changes in 
approximately one out of every 40 cases. Further research is 
required to determine the essential elements of peer review, and 
to assess the impact of peer review on clinical outcomes.  
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Purpose: Physics-based assessment tools were developed to 
utilize transmission EPID data acquired during treatment to 
reconstruct in vivo 3D dose for every fraction of patients treated 
with stereotactic body radiation therapy (SBRT). This method 
provides verification of inter-fractional dose delivery to capture 
treatment delivery errors midway through treatment, allowing 
potential corrective interventions to reduce the radiobiological 
impact on patients given the high dose per fraction delivered in 
SBRT. In this study, the two-year results of our implemented 
EPID-based dose verification system are presented. 
Methods and Materials: Based on our initial experiences, several 
enhancements were implemented to improve comparison 
between the EPID and treatment planning system 3D doses 
including, patient-specific EPID frame averaging optimization, 
